Trevi Therapeutics, Inc. Research and Development Expense
Trevi Therapeutics, Inc. (TRVI) reported Research and Development Expense of $15.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Trevi Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $15.15M, a 61.38% increase year-over-year.
- Trevi Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $9.94M, a 27.27% increase year-over-year.
- Trevi Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $6.19M, a 33.61% decline year-over-year.
- Trevi Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $10.09M, a 10.15% decline year-over-year.
- Trevi Therapeutics, Inc. research and development expense for fiscal 2025 was $33.48M, a 14.98% decline from fiscal 2024.
- Trevi Therapeutics, Inc. research and development expense for fiscal 2024 was $39.38M, a 66.27% increase from fiscal 2023.
- Trevi Therapeutics, Inc. research and development expense for fiscal 2023 was $23.68M, a 19.41% increase from fiscal 2022.
- Trevi Therapeutics, Inc. research and development expense for fiscal 2022 was $19.83M, a 13.71% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.15M 10-Q · filed 2026-08-06 | $25.09M 10-Q · filed 2026-08-06 | $31.29M derived: sum of 3 quarters · filed 2026-08-06 | $41.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.94M 10-Q · filed 2026-05-05 | $16.13M derived: sum of 2 quarters · filed 2026-05-05 | $26.22M derived: sum of 3 quarters · filed 2026-05-05 | $35.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $16.28M derived: sum of 2 quarters · filed 2026-03-17 | $25.67M derived: sum of 3 quarters · filed 2026-08-06 | $33.48M 10-K · filed 2026-03-17 |
| 2025-09-30 | $10.09M 10-Q · filed 2025-11-13 | $19.47M derived: sum of 2 quarters · filed 2026-08-06 | $27.29M 10-Q · filed 2025-11-13 | $36.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $9.39M 10-Q · filed 2026-08-06 | $17.20M 10-Q · filed 2026-08-06 | $26.53M derived: sum of 3 quarters · filed 2026-08-06 | $37.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.81M 10-Q · filed 2026-05-05 | $17.14M derived: sum of 2 quarters · filed 2026-05-05 | $28.36M derived: sum of 3 quarters · filed 2026-05-05 | $38.38M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $9.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $20.55M derived: sum of 2 quarters · filed 2026-03-17 | $30.57M derived: sum of 3 quarters · filed 2026-03-17 | $39.38M 10-K · filed 2026-03-17 |
| 2024-09-30 | $11.22M 10-Q · filed 2025-11-13 | $21.25M derived: sum of 2 quarters · filed 2025-11-13 | $30.05M 10-Q · filed 2025-11-13 | $36.57M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $10.02M 10-Q · filed 2025-08-07 | $18.82M 10-Q · filed 2025-08-07 | $25.34M derived: sum of 3 quarters · filed 2025-08-07 | $31.67M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $8.80M 10-Q · filed 2025-05-08 | $15.32M derived: sum of 2 quarters · filed 2025-05-08 | $21.64M derived: sum of 3 quarters · filed 2025-05-08 | $27.49M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $12.84M derived: sum of 2 quarters · filed 2025-03-18 | $18.68M derived: sum of 3 quarters · filed 2025-03-18 | $23.68M 10-K · filed 2025-03-18 |
| 2023-09-30 | $6.32M 10-Q · filed 2024-11-06 | $12.16M derived: sum of 2 quarters · filed 2024-11-06 | $17.16M 10-Q · filed 2024-11-06 | $21.48M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $5.84M 10-Q · filed 2024-08-08 | $10.84M 10-Q · filed 2024-08-08 | $15.16M derived: sum of 3 quarters · filed 2024-08-08 | $20.93M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.00M 10-Q · filed 2024-05-07 | $9.32M derived: sum of 2 quarters · filed 2024-05-07 | $15.09M derived: sum of 3 quarters · filed 2024-05-07 | $20.19M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $10.09M derived: sum of 2 quarters · filed 2024-03-20 | $15.19M derived: sum of 3 quarters · filed 2024-03-20 | $19.83M 10-K · filed 2024-03-20 |
| 2022-09-30 | $5.77M 10-Q · filed 2023-11-09 | $10.87M derived: sum of 2 quarters · filed 2023-11-09 | $15.52M 10-Q · filed 2023-11-09 | $21.70M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $5.10M 10-Q · filed 2023-08-10 | $9.75M 10-Q · filed 2023-08-10 | $15.93M derived: sum of 3 quarters · filed 2023-08-10 | $20.64M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $4.64M 10-Q · filed 2023-05-11 | $10.82M derived: sum of 2 quarters · filed 2023-05-11 | $15.54M derived: sum of 3 quarters · filed 2023-05-11 | $22.04M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $6.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $10.90M derived: sum of 2 quarters · filed 2023-03-16 | $17.39M derived: sum of 3 quarters · filed 2023-03-16 | $22.98M 10-K · filed 2023-03-16 |
| 2021-09-30 | $4.72M 10-Q · filed 2022-11-10 | $11.22M derived: sum of 2 quarters · filed 2022-11-10 | $16.80M 10-Q · filed 2022-11-10 | $23.36M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $6.50M 10-Q · filed 2022-08-11 | $12.09M 10-Q · filed 2022-08-11 | $18.65M derived: sum of 3 quarters · filed 2022-08-11 | $23.48M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $5.59M 10-Q · filed 2022-05-12 | $12.15M derived: sum of 2 quarters · filed 2022-05-12 | $16.98M derived: sum of 3 quarters · filed 2022-05-12 | $21.90M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $11.39M derived: sum of 2 quarters · filed 2022-03-17 | $16.31M derived: sum of 3 quarters · filed 2022-03-17 | $22.33M 10-K · filed 2022-03-17 |
| 2020-09-30 | $4.83M 10-Q · filed 2021-11-10 | $9.75M derived: sum of 2 quarters · filed 2021-11-10 | $15.77M 10-Q · filed 2021-11-10 | $20.59M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $4.92M 10-Q · filed 2021-08-12 | $10.94M 10-Q · filed 2021-08-12 | $15.76M derived: sum of 3 quarters · filed 2021-08-12 | $21.41M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $6.02M 10-Q · filed 2021-05-13 | $10.84M derived: sum of 2 quarters · filed 2021-05-13 | $16.49M derived: sum of 3 quarters · filed 2021-05-13 | $22.02M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $10.47M derived: sum of 2 quarters · filed 2021-03-25 | $16.00M derived: sum of 3 quarters · filed 2021-03-25 | $19.34M 10-K · filed 2021-03-25 |
| 2019-09-30 | $5.65M 10-Q · filed 2020-11-12 | $11.18M derived: sum of 2 quarters · filed 2020-11-12 | $14.52M 10-Q · filed 2020-11-12 | $19.04M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $5.53M 10-Q · filed 2020-08-13 | $8.87M 10-Q · filed 2020-08-13 | $13.39M derived: sum of 3 quarters · filed 2020-08-13 | $17.14M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $3.34M 10-Q · filed 2020-05-07 | $7.86M derived: sum of 2 quarters · filed 2020-05-07 | $11.61M derived: sum of 3 quarters · filed 2020-05-07 | $15.05M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $8.27M derived: sum of 2 quarters · filed 2020-03-16 | $11.71M derived: sum of 3 quarters · filed 2020-03-16 | $14.07M 10-K · filed 2020-03-16 |
| 2018-09-30 | $3.75M 10-Q · filed 2019-11-14 | $7.19M derived: sum of 2 quarters · filed 2019-11-14 | $9.55M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $3.44M 10-Q · filed 2019-08-12 | $5.80M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $2.36M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |